Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Mar;117(5):867–872. doi: 10.1111/j.1476-5381.1996.tb15273.x

Enhancement of sympathetic purinergic neurotransmission in the guinea-pig isolated vas deferens by the novel ecto-ATPase inhibitor ARL 67156.

T D Westfall 1, C Kennedy 1, P Sneddon 1
PMCID: PMC1909408  PMID: 8851503

Abstract

1. Field stimulation of the sympathetic nerves of the guinea-pig isolated vas deferens with trains of pulses of 20 s at 1-8 Hz produced characteristic biphasic contractions. The effect of the novel ecto-ATPase inhibitor, 6-N,N-diethyl-D-beta, gamma-dibromomethyleneATP (ARL 67156, formerly known as FPL 67156), on the magnitude of the initial, predominantly purinergic peak of this response was studied in order to determine the influence of enzymatic degradation of adenosine 5'-triphosphate (ATP) on its action as a neurotransmitter. 2. The peak magnitude of the response to nerve stimulation was significantly increased in a concentration-dependent manner by ARL 67156 (5-100 microM) and the size of the neurogenic response at 4 Hz was approximately doubled in the presence of ARL 67156 (100 microM). 3. ARL 67156 (100 microM) has a rapid onset of action. The enhancing effect on neurogenic contractions was maximal after 10 min, was well maintained for at least 30 min and was rapidly reversed, with responses returning to control levels 10 min after washout. 4. The neurogenic contraction in the presence of prazosin (0.1 microM) was purely purinergic, as it was abolished by the P2-purinoceptor antagonist, PPADS (100 microM). ARL 67156 (100 microM) produced a similar degree of enhancement of neurogenic responses in the absence and presence of prazosin, supporting the view that the enhancing effects of ARL 67156 on neurogenic contractions result from potentiation of the action of ATP. 5. Exogenous ATP and alpha, beta-methyleneATP produced rapid transient contractions. Responses to ATP were increased in magnitude and duration in the presence of ARL 67156 (100 microM), whereas those to the stable analogue, alpha, beta-methylene ATP were not significantly affected. 6. Contractions to exogenous noradrenaline (10 microM) and KCl (40 mM) were significantly enhanced by ARL 67156 (100 microM), but this potentiation was abolished by PPADS (100 microM). Therefore, this effect of the ecto-ATPase inhibitor may be due to a build up of endogenous ATP, increasing the sensitivity of the smooth muscle to other agonists. 7. It is concluded that ARL 67156 potentiates the action of ATP, and that when ATP acts as a neurotransmitter its postjunctional actions are greatly attenuated by enzymatic degradation.

Full text

PDF
867

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bailey S. J., Hourani S. M. Differential effects of suramin on P2-purinoceptors mediating contraction of the guinea-pig vas deferens and urinary bladder. Br J Pharmacol. 1994 May;112(1):219–225. doi: 10.1111/j.1476-5381.1994.tb13055.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Boyer J. L., Zohn I. E., Jacobson K. A., Harden T. K. Differential effects of P2-purinoceptor antagonists on phospholipase C- and adenylyl cyclase-coupled P2Y-purinoceptors. Br J Pharmacol. 1994 Oct;113(2):614–620. doi: 10.1111/j.1476-5381.1994.tb17034.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Burnstock G., Kennedy C. Is there a basis for distinguishing two types of P2-purinoceptor? Gen Pharmacol. 1985;16(5):433–440. doi: 10.1016/0306-3623(85)90001-1. [DOI] [PubMed] [Google Scholar]
  4. Burnstock G. Overview. Purinergic mechanisms. Ann N Y Acad Sci. 1990;603:1–18. doi: 10.1111/j.1749-6632.1990.tb37657.x. [DOI] [PubMed] [Google Scholar]
  5. Burnstock G. Purinergic nerves. Pharmacol Rev. 1972 Sep;24(3):509–581. [PubMed] [Google Scholar]
  6. Crack B. E., Pollard C. E., Beukers M. W., Roberts S. M., Hunt S. F., Ingall A. H., McKechnie K. C., IJzerman A. P., Leff P. Pharmacological and biochemical analysis of FPL 67156, a novel, selective inhibitor of ecto-ATPase. Br J Pharmacol. 1995 Jan;114(2):475–481. doi: 10.1111/j.1476-5381.1995.tb13251.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Culic O., Huang Q. H., Flanagan D., Hixson D., Lin S. H. Molecular cloning and expression of a new rat liver cell-CAM105 isoform. Differential phosphorylation of isoforms. Biochem J. 1992 Jul 1;285(Pt 1):47–53. doi: 10.1042/bj2850047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cunnane T. C., Manchanda R. Electrophysiological analysis of the inactivation of sympathetic transmitter in the guinea-pig vas deferens. J Physiol. 1988 Oct;404:349–364. doi: 10.1113/jphysiol.1988.sp017293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Driessen B., von Kügelgen I., Starke K. P1-purinoceptor-mediated modulation of neural noradrenaline and ATP release in guinea-pig vas deferens. Naunyn Schmiedebergs Arch Pharmacol. 1994 Jul;350(1):42–48. doi: 10.1007/BF00180009. [DOI] [PubMed] [Google Scholar]
  10. Dzhandzhugazyan K., Bock E. Demonstration of (Ca(2+)-Mg2+)-ATPase activity of the neural cell adhesion molecule. FEBS Lett. 1993 Dec 27;336(2):279–283. doi: 10.1016/0014-5793(93)80820-k. [DOI] [PubMed] [Google Scholar]
  11. Edlund M., Gaardsvoll H., Bock E., Obrink B. Different isoforms and stock-specific variants of the cell adhesion molecule C-CAM (cell-CAM 105) in rat liver. Eur J Biochem. 1993 May 1;213(3):1109–1116. doi: 10.1111/j.1432-1033.1993.tb17860.x. [DOI] [PubMed] [Google Scholar]
  12. Gordon J. L. Extracellular ATP: effects, sources and fate. Biochem J. 1986 Jan 15;233(2):309–319. doi: 10.1042/bj2330309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Harris G. S. ATPase activity of pharmacological preparations. Eur J Pharmacol. 1972 Jul;19(1):137–139. doi: 10.1016/0014-2999(72)90091-x. [DOI] [PubMed] [Google Scholar]
  14. Holck M. I., Marks B. H. Purine nucleoside and nucleotide interactions on normal and subsensitive alpha adrenoreceptor responsiveness in guinea-pig vas deferens. J Pharmacol Exp Ther. 1978 Apr;205(1):104–117. [PubMed] [Google Scholar]
  15. Katsuragi T., Tokunaga T., Ogawa S., Soejima O., Sato C., Furukawa T. Existence of ATP-evoked ATP release system in smooth muscles. J Pharmacol Exp Ther. 1991 Nov;259(2):513–518. [PubMed] [Google Scholar]
  16. Kazić T., Milosavljević D. Interaction between adenosine triphosphate and noradrenaline in the isolated vas deferens of the guinea-pig. Br J Pharmacol. 1980;71(1):93–98. doi: 10.1111/j.1476-5381.1980.tb10913.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kennedy C., Leff P. How should P2X purinoceptors be classified pharmacologically? Trends Pharmacol Sci. 1995 May;16(5):168–174. doi: 10.1016/s0165-6147(00)89010-0. [DOI] [PubMed] [Google Scholar]
  18. McCuaig K., Rosenberg M., Nédellec P., Turbide C., Beauchemin N. Expression of the Bgp gene and characterization of mouse colon biliary glycoprotein isoforms. Gene. 1993 May 30;127(2):173–183. doi: 10.1016/0378-1119(93)90716-G. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. McLaren G. J., Lambrecht G., Mutschler E., Bäumert H. G., Sneddon P., Kennedy C. Investigation of the actions of PPADS, a novel P2x-purinoceptor antagonist, in the guinea-pig isolated vas deferens. Br J Pharmacol. 1994 Mar;111(3):913–917. doi: 10.1111/j.1476-5381.1994.tb14825.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Najjar S. M., Accili D., Philippe N., Jernberg J., Margolis R., Taylor S. I. pp120/ecto-ATPase, an endogenous substrate of the insulin receptor tyrosine kinase, is expressed as two variably spliced isoforms. J Biol Chem. 1993 Jan 15;268(2):1201–1206. [PubMed] [Google Scholar]
  21. O'Connor S. E., Dainty I. A., Leff P. Further subclassification of ATP receptors based on agonist studies. Trends Pharmacol Sci. 1991 Apr;12(4):137–141. doi: 10.1016/0165-6147(91)90530-6. [DOI] [PubMed] [Google Scholar]
  22. Sakai K. K., Hymson D. L., Shapiro R. The effects of adenosine and adenine nucleotides on the guinea-pig vas deferens: evidence for existence of purinergic receptors. Life Sci. 1979 Apr 2;24(14):1299–1308. doi: 10.1016/0024-3205(79)90149-8. [DOI] [PubMed] [Google Scholar]
  23. Sneddon P., Meldrum L. A., Burnstock G. Control of transmitter release in guinea-pig vas deferens by prejunctional P1-purinoceptors. Eur J Pharmacol. 1984 Oct 15;105(3-4):293–299. doi: 10.1016/0014-2999(84)90621-6. [DOI] [PubMed] [Google Scholar]
  24. Sneddon P., Westfall D. P., Fedan J. S. Cotransmitters in the motor nerves of the guinea pig vas deferens: electrophysiological evidence. Science. 1982 Nov 12;218(4573):693–695. doi: 10.1126/science.6291151. [DOI] [PubMed] [Google Scholar]
  25. Sneddon P., Westfall D. P. Pharmacological evidence that adenosine triphosphate and noradrenaline are co-transmitters in the guinea-pig vas deferens. J Physiol. 1984 Feb;347:561–580. doi: 10.1113/jphysiol.1984.sp015083. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Somlyo A. P., Somlyo A. V. Signal transduction and regulation in smooth muscle. Nature. 1994 Nov 17;372(6503):231–236. doi: 10.1038/372231a0. [DOI] [PubMed] [Google Scholar]
  27. Vizi E. S., Sperlágh B., Baranyi M. Evidence that ATP released from the postsynaptic site by noradrenaline, is involved in mechanical responses of guinea-pig vas deferens: cascade transmission. Neuroscience. 1992 Sep;50(2):455–465. doi: 10.1016/0306-4522(92)90437-7. [DOI] [PubMed] [Google Scholar]
  28. Walsh M. P. Regulation of vascular smooth muscle tone. Can J Physiol Pharmacol. 1994 Aug;72(8):919–936. doi: 10.1139/y94-130. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES